AS MDI

DRUG3 trials

Sponsors

AstraZeneca, Bond Avillion 2 Development LP

Conditions

Asthma

Phase 2

Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma

CompletedNCT03371459

AstraZenecaAsthma

Start: 2017-12-29End: 2018-03-26Updated: 2019-07-23

Phase 3

A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma

CompletedNCT05505734

Bond Avillion 2 Development LPAsthma

Start: 2022-09-02End: 2024-08-22Updated: 2025-08-03

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma

RecruitingNCT06307665

AstraZenecaAsthma

Start: 2024-05-20End: 2027-10-13Target: 440Updated: 2026-08-13

Related Papers

Efficacy and safety of as-needed albuterol-budesonide versus albuterol in patients with asthma aged 12 to <18 years: design of the randomised, double-blind, parallel-group phase IIIb ACADIA trial.

2026-03-06

As-Needed Albuterol–Budesonide in Mild Asthma

New England Journal of Medicine2025-05-1912 citations

A Fully Decentralized Randomized Controlled Study of As-Needed Albuterol-Budesonide Fixed-Dose Inhaler in Mild Asthma: The BATURA Study Design.

2024-08-234 citations

Dose-Ranging and Cumulative Dose Studies of Albuterol Sulfate MDI in Co-Suspension Delivery™ Technology (AS MDI; PT007) in Patients with Asthma: the ASPEN and ANTORA Trials.

2021-06-044 citations